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Abstract
Indigenous Australian children have high (up to 90%) rates of nasopharyngeal microbial colonisation and of 
hospitalisation for pneumonia. In Indigenous children hospitalised with pneumonia in Central Australia, we describe 
the nasopharyngeal detection of viruses and bacteria and assessed whether their presence related to signs of 
pneumonia (tachypnoea and/or chest in-drawing) on hospital admission and during subsequent days. Nasopharyngeal 
swabs (NPS) and data were prospectively collected from 145 children (median age = 23.5 months, interquartile range 
[IQR] 8.7–50) hospitalised with pneumonia at Alice Springs Hospital, Australia, between April 2001 and July 2002. 
The cohort was enrolled in a randomised controlled study using zinc and/or vitamin A supplementation. NPS were 
taken within 24 hours of hospitalisation and kept frozen at -80oC until analysed in 2014. Polymerase chain reaction 
(PCR) was used to detect Moraxella catarrhalis, Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus 
aureus, Chlamydophila pneumoniae, Mycoplasma pneumoniae, and 16 respiratory viruses. Uni- and multi-variate 
analyses were used to examine the relationships. One or more organisms were present in 137 (94.5%) NPS; 133 
(91.7%) detected ≥ 1 bacterium, 34 (37.2%) for ≥ 1 virus and 50 (34.5%) were positive for both viruses and bacteria. 
C. pneumoniae (n = 3) and M. pneumoniae (n = 2) were rare. In multi-variate analyses, age < 12 months (odds ratio [OR] 
6.6 [95% confidence interval {CI} 1.7–25.4]) and fever (OR 4.1 [95% CI 1.7–10.4]) were associated with tachypnoea 
and chest in-drawing. However the presence of bacteria and/or virus type was not associated with tachypnoea and/
or chest in-drawing on admission or during recovery. In children with high nasopharyngeal microbial colonisation 
rates, the utility of NPS in determining the diagnosis of clinical pneumonia or duration of tachypnoea or in-drawing is 
likely limited. Larger cohort and case-control studies are required to confirm our findings.
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1. Introduction
Reported hospitalisation rates for acute lower respiratory 
infections (ALRIs), including pneumonia, in Indigenous 
Australian children from remote areas are comparable 
to and, in some regions, higher than those for children in 
developing countries [1]. Despite the burden, to date, there 
has been only one study that has examined upper airway 
viruses and bacteria in Indigenous Australian children 
from remote communities who have been hospitalised for 
ALRI [2]. This study was conducted prior to the availability 
of molecular diagnostic methods [2].
There are few studies that have used the World Health 
Organization’s (WHO) [3] clinical diagnostic criteria 
together with current extended molecular methods to 
examine the relationship between both upper airway 
viruses and bacteria and clinical and/or radiologically 
confirmed pneumonia, and its outcomes, in children. The 
majority of studies have focused on specific viruses [4,5] 
or bacteria [6,7,8], with few assessing whether upper 
airway microbiology predicts clinical symptoms. There 
are none that have been conducted in a population with 
a similar pneumonia risk to that of Central Australian 
Indigenous children. Use of nasopharyngeal swabs (NPS) 
is convenient, as obtaining lower airway specimens in very 
young children generally requires invasive procedures 
(e.g. bronchoscopy or lung punctures). However, NPS 
taken at hospitalisation may not reflect clinical symptoms 
or outcomes as nasopharyngeal (NP) carriage in this 
population is high (up to 90% of asymptomatic children) 
[9,10] and detection of organisms by polymerase chain 
reaction (PCR) at a single point in time does not necessarily 
equate to active infection. Further, carriage of NP viruses is 
as high as 45% of asymptomatic hospitalised children [11].
In 145 Central Australian Indigenous children hospitalised 
with pneumonia, we describe the point prevalence of 
NP bacteria and viruses in these children and assessed 
whether viruses and bacteria detected in the NP related 
to the WHO clinical definition for pneumonia (tachypnoea 
and/or chest in-drawing) on admission and the duration 
of these signs. Given the usually high level of NP carriage 
of bacteria and viruses in children without pneumonia 
in our target group, we hypothesised that there was no 
relationship between these upper airway microbes and 
clinical symptoms.
2. Methods
2.1 Setting
The study was undertaken between April 2001 and July 
2002 at the Alice Springs Hospital, Northern Territory, 
Australia, the sole hospital servicing the region. The 
Alice Springs Hospital is a 189-bed hospital in the Central 
Australian desert region and serves a population of 
approximately 60,000 persons dispersed across 1.6 
million2 kilometres. Forty per cent of the population is 
Aboriginal, most of who reside in remote communities. 
At the time of the study, Central Australian Aboriginal 
children had been receiving Haemophilus influenzae type 
b vaccine (Hib), PRP–OMP conjugate, since 1992 at ages 2, 
4 and 12 months. In June 2001 (during study recruitment), 
the 7-valent pneumococcal conjugate vaccine (PCV7) was 
introduced to the routine schedule, administered at 2, 4, 
and 6 months of age with a booster dose of the 23-valent 
pneumococcal polysaccharide vaccine at 18 months of 
age. In our setting, children with clinically suspected 
pneumonia are treated in community clinics according 
to standard treatment protocols and retrieval to hospital 
occurs when oxygen is required or the child “fails to 
respond to treatment”.
2.2 Study design
We used data collected prospectively during a randomised 
controlled trial (RCT) of zinc and vitamin A supplementation 
in 215 Central Australian Aboriginal children (aged <11 
years) hospitalised with pneumonia [12]. All children 
enrolled in the trial had an illness with cough, tachypnoea, 
and documented fever (≥38.5°C) or pneumonia diagnosed 
by chest radiograph (CXR), when referred to the hospital. 
Blood culture was taken as part of the clinical routine care 
in the hospital.
The inclusion criteria for the RCT [12] were: (a) an illness with 
tachypnoea and either documented fever (temperature 
≥38.5°C) or chest in-drawing; or (b) pneumonia diagnosed 
by CXR. Tachypnoea was defined as respiratory rate at or 
above 60 breaths per minute (age <2 months), 50 breaths 
per minute (age 2–11 months), or 40 breaths per minute 
(age 12–59 months), or an arbitrary cut-off of 30 breaths 
per minute at age 5 years and over. Exclusion criteria for the 
RCT were presence of bronchiolitis syndrome (wheezing, 
coryza), or chronic lung, gastrointestinal, or neurological 
disease.
Informed consent was obtained from the carer(s) by a 
research nurse or a member of the research team. Detailed 
clinical data (antibiotics prior to admission, fever, duration 
of fever, tachypnoea, chest in-drawing) and demographic 
data (gender, birth weight, age, prior pneumonia 
hospitalisation) were collected using standardised case 
report forms. NPS were collected after enrollment and 
within 24 hours of admission to the paediatric ward. 
For this study, we assessed the signs that compromise 
the WHO definition for clinical pneumonia (tachypneoa 
and/or chest in-drawing). Accessory muscle use (for 
assessment of chest in-drawing) and the child’s respiratory 
rate were documented after observing the child for 60 
seconds after oxygen had been turned off (if applicable). 
These assessments were undertaken by trained research 
nurses twice a day but, given the known variability in 
children’s respiratory status, only the more severe (higher) 
rate was recorded on a daily basis. The total hours of fever 
and tachypnoea and total days of chest in-drawing were 
calculated.
Of the 215 episodes of hospitalised pneumonia included 
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in the RCT, 57 were excluded from this study as swabs 
were not available and a further 13 were excluded as the 
swab was not taken within 24 hours of admission. The final 
dataset for this paper therefore comprised 145 episodes.
2.3 Laboratory
NPS, stored in skim milk tryptone glucose glycerol broth, 
were kept frozen at -80°C until analysed in 2014. We 
have previously demonstrated that our stored NPS (at 
-80°C) are valid for viral and bacterial identification and 
quantification by culture and PCR [13,14]. Both viral and 
bacterial detection by PCR were undertaken in accordance 
to established methods in our laboratories [9,13,14,15].
Virus testing was conducted at the Queensland Paediatric 
Infectious Diseases (QPiD) Laboratory, Queensland, 
Australia, for 16 viruses according to previously described 
PCR methods [9,15]. These viruses included human 
rhinovirus, adenovirus, respiratory syncytial virus (RSV), 
influenza virus types A and B, parainfluenza virus types 
1–3, human metapneumovirus, human coronaviruses 
(OC43, 229E, NL63, and HKU1), human bocavirus, and 
human polyomaviruses KI and WU. QPiD Laboratory also 
performed PCR testing for Chlamydophila pneumoniae and 
Mycoplasma pneumoniae. Quantitative PCR for Moraxella 
catarrhalis, H. influenzae, Streptococcus pneumoniae and 
Staphylococcus aureus was performed at the Menzies 
School of Health of Research Laboratory, Darwin, Australia, 
according to previously published methods [16,17].
2.4 Ethics statement
The primary study was approved by the Central Australian 
Ethics Committee and the Queensland Institute of Medical 
Research (Approval number: P326). Informed written 
consent was obtained from a parent/carer. This study 
was conducted under the provisions of the Declaration of 
Helsinki.
2.5 Statistics
Chi-squared tests were used to compare categorical 
variables (fever present, antibiotics prior to admission, age 
categories, presence of the various bacteria and viruses). 
For multi-variate analyses, variables with p values of < 0.2 
in univariate analysis were used in the model to provide 
adjusted odds ratios (ORs). All statistical analyses were 
performed using Stata version 12 (USA).
Given the small number of observations of individual 
viruses, we classified viruses into two groups [11]: 
Group A = RSV, influenza virus types A and B, human 
metapneumovirus, adenovirus and parainfluenza viruses 
types 1–3; Group B = human rhinovirus, human bocavirus, 
human polyomaviruses K1 and WU, human coronaviruses 
OC43, 229E, NL63, and HKU1. The grouping of the viruses 
is controversial. The primary reason for this classification 
is based on the high prevalence of Group B viruses in 
asymptomatic children, whereas detection of Group A 
viruses is mostly associated with respiratory symptoms 
[11,18,19,20].
3. Results
The children’s median age was 23.5 months (interquartile 
range [IQR] 8.7–50.0); other data are presented in Table 
1. In 138 (95.2%) episodes a blood culture was taken: 11 
(8.0%) were culture positive; 1 was positive for Hib, 1 for 
S. pneumoniae, 1 for S. aureus, and the remainder were 
considered contaminants.
Table 1 Demographic data of the cohort
Characteristic Number of patients (%)
Gender
Male 80 (55.1)
Female 65 (44.8)
Birth weighta
<2500 grams 12 (9.0)
≥2500 grams 122 (91.0)
Gestational agea
<37 weeks 15 (11.3)
≥37 weeks 118 (88.7)
Prior pneumonia hospitalisation
Yes 62 (45.3)
No 75 (54.7)
3.1 Point prevalence of bacteria and viruses in the NPS
Most swabs (n =137 [94.5%]) were positive for at least 1 
organism (Table 2): there was at least 1 bacterium in 91.7% 
of the NPS, and at least 1 virus in 37.2%. Human rhinovirus 
and the polyomaviruses K1 and WU were the most 
commonly detected viruses, 24.7% and 9.0%, respectively. 
Organisms infrequently detected were C. pneumoniae 
(n = 3 [2.1%]), M. pneumoniae (n = 2 [1.4%]), influenza 
virus (either A or B) (n = 6 [4.1%]), RSV (n = 2 [1.4%]), 
parainfluenza virus type 3 (n = 3 [2.1%]), adenovirus (n = 
2 [1.4%]), bocavirus (n = 2 [1.4%]), and coronavirus NL63 
(n = 1 [0.7%]). There were no positive detections of S. 
aureus, human metapneumovirus, parainfluenza virus 
types (1 or 2), or coronaviruses HKU1, OC43, or 229E.
3.2 Relationship between NPS microbial, clinical signs and 
duration of clinical signs
Table 2 presents the relationship between child 
characteristics, organism identified, and the presence of 
tachypnoea and/or chest in-drawing. In both univariate 
and regressions models (data not shown), there were no 
covariates significantly associated with tachypnoea. In 
univariate analyses, age, fever (≥38.5oC) on admission, and 
being H. influenzae and M. catarrhalis positive on NPS were 
associated with chest in-drawing. In adjusted analyses 
asome data missing 
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only age <12 months (OR 6.6 [95% confidence interval {CI} 
1.7–25.4]) and fever (OR 4.1 [95% CI 1.7–10.4]) remained 
associated with chest in-drawing. Similarly, age <12 
months and fever were associated with tachypnoea and 
chest in-drawing combined in analyses that adjusted for 
gender, age, prematurity, comorbidity of gastroenteritis, 
and fever. Presence of bacteria and/or virus type was not 
associated with tachypnoea and/or chest in-drawing, in 
multi-variate analyses. No microbiological associations 
were found in relation to duration of fever, tachypnoea, or 
chest in-drawing (Table 3).
4. Discussion
In 145 Central Australian Indigenous children hospitalised 
with pneumonia, a very high prevalence of bacteria 
(91.7%) or virus (37.2%) were detected in the NPS and 
multiple co-infection was common. Mycoplasma (1.4%) 
and chlamydia (2.1%) were rare. We found no significant 
relationship between the NP presence of types of bacteria 
and/or viruses with signs on admission (chest in-drawing, 
tachypnoea, fever) or the duration of signs.
We are unaware of any published data (PubMed [http://
www.ncbi.nlm.nih.gov/pubmed] search February 2015) 
evaluating the relationship between signs of pneumonia 
and recovery of children hospitalised with ALRI and upper 
airway bacteria and viruses in a setting with a high acute 
[1] and chronic [21] respiratory burden. In other settings, 
there are many studies that have described the positive 
association between NP microbiology and ALRI symptoms 
[22] or pneumonia [8,23,24], but few have evaluated 
signs of WHO-defined clinical pneumonia to both viral 
and bacteria detection in the upper airways. Some 
studies assume that what is found in the upper airways 
is the aetiological cause of the pneumonia [23,24], and 
others advocated that microbiology (e.g. pneumococcus) 
identified on NPS can be used to diagnose aetiology of 
pneumonia [6]. However, we have previously shown that 
the yield of respiratory virus detection in NP aspirates 
versus broncho-alveolar lavage is dependent on virus 
type [25]. Indeed, delineating the aetiological agent 
of pneumonia is not straightforward when the direct 
lower airway specimens (e.g. sputum, lung biopsy) are 
unavailable and in the absence of a positive blood culture 
[26]. Complexities include the case definition, use of 
and interpretation of CXR, blood white cell counts and 
inflammatory markers, depth of investigations, facility 
type, and patient characteristics [26], as well as the 
limited specificity of the WHO diagnosis of pneumonia and 
CXRs [27]. None of the studies have examined recovery 
of these signs of clinical pneumonia and it is also likely 
Table 3 Relationship between nasopharyngeal microbiology and duration of symptoms in Central Australian Aboriginal children 
hospitalised with pneumonia
Nasopharyngeal microbiology Fever Tachypnoea Chest in-drawing
Median no. 
hours (IQR)
p-value Median no. 
hours (IQR)
p-value Median no. days   
(95% CI)
p-value
Streptococcus pneumoniae positive
Yes 11 (5–15) 0.923 9 (0–19) 0.431 1.76 (1.28–2.23) 0.974
No 9.5 (6.5–24.5) 10 (0–25) 1.75 (1.20–2.30)
Haemophilus influenzae positive
Yes 11 (5–24) 0.71 8.5 (0–24) 0.661 1.70 (1.29–2.13) 0.641
No 12 (8–24) 10 (10–17) 1.89 (1.18–2.60)
Moraxella catarrhalis positive
Yes 11 (5–24) 0.763 10 (0–24) 0.788 1.79 (1.27–2.31) 0.829
No 11 (5–27) 10 (0–17) 1.71 (1.24–2.19)
Group A virus present
Yes 10 (7–25) 0.966 0 (0–24) 0.739 2.00 (0.48–3.52) 0.552
No 11 (5–24) 10 (0–21) 1.71 (1.35–2.08)
Group B virus present
Yes 9 (7–12) 0.219 8 (0–10) 0.128 1.64 (1.02–2.26) 0.619
No 11.5 (5–25) 11.5 (0–24) 1.82 (1.37–2.26)
Virus and bacteria positive
Yes 8 (11–15) 0.866 8 (0–12) 0.497 1.67 (1.10–2.23) 0.691
No 11 (5–24.5) 10.5 (0–24) 1.80 (1.34–2.28)
Note: Group A viruses = respiratory syncytial virus, influenza virus types A and B, human metapneumovirus, adenovirus and 
parainfluenza viruses types 1–3; Group B viruses = viruses commonly detected in asymptomatic children and those with acute lower 
respiratory infection (human rhinovirus, human bocavirus, human polyomaviruses K1 and WU, human coronaviruses OC43, 229E, 
NL63 and HKU1).
CI, confidence interval; IQR, interquartile range
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that these studies have limited applicability in settings 
with a high infectious burden from a young age; e.g. in 
Indigenous Australian remote communities and very 
low-income countries. Our study thus contributes to the 
medical literature on childhood pneumonia, in spite of the 
limitations of our study as discussed below.
Our negative findings are likely to be influenced by the 
very high carriage rates of bacteria in this population from 
an early age [10, 13], resulting in only a very small number 
of children who were not positive for any organism. The 
very high carriage rates of the key respiratory bacteria in 
Indigenous Australian children in remote communities are 
well established, with respiratory bacteria NP colonisation 
rate of up to 90% [10]. Also, colonisation occurs very 
early in life (as young as 2 weeks) [10,28]. From birth, 
the nasopharynx of Indigenous Australian infants are 
“colonized with multiple species of respiratory bacteria (M. 
catarrhalis, H. influenzae, S. pneumoniae) at a rate of 5% 
per day” [28]. Similarly, M. catarrhalis (96%), H. influenzae 
(91%), S. pneumoniae (89%), and respiratory viruses (59%) 
were identified in NPS of 114 Indigenous children from 
remote communities, with and without acute otitis media 
[13] and without pneumonia.
In contrast to our findings, a German study (a low baseline 
carriage setting) involving 311 children with ALRI [6] 
described that bacteria in the NP were associated with 
some clinical features and outcomes. Among other 
findings, the study described that children with S. aureus 
positive co-colonisation received more antibiotics (p = 
0.004), received more frequent CXRs (p = 0.05), and stayed 
longer in hospital (p = 0.0003) than those with S. aureus 
single colonisation [6]. However, the study did not examine 
for viruses and only 102 children had pneumonia (the 
remainder had a wheezing illness and hence the illness 
was most likely a viral ALRI). Thus, the German study is 
incomparable to our study. Our study had low prevalence 
of RSV and influenza virus, which is not unexpected given 
that children with bronchiolitis symptoms (e.g. wheezing) 
were excluded.
Our study was an opportunistic evaluation of NP 
microbiology within a RCT, and hence the association 
component of our findings has many limitations. Firstly, 
the sample size is relatively small and thus we had limited 
power to detect small differences between groups with 
certainty, and examination of interactions could not be 
validly performed. Secondly, we did not have a control 
group to contemporaneously evaluate if NP carriage in 
children hospitalised with pneumonia was higher than 
those hospitalised for other reasons; however, our study’s 
aim was to evaluate NP microbiology with symptoms and 
signs of pneumonia and not between groups of children 
with different diseases. Thirdly, the majority of children 
(73%) were from remote communities and their clinical 
presentation at time of admission to the ward would have 
been influenced by treatment (e.g. antipyretics, oxygen 
therapy, prior antibiotics) prior to retrieval to hospital. It 
is likely that more children would have had clinical signs 
suggestive of pneumonia when they presented to the 
remote community clinic. However, this scenario of prior 
treatment and delay prior to management in a major 
hospital is similar to some regions in developing countries 
where treatment is initiated in the local clinic and the child 
transferred to a major hospital if required. Nevertheless, 
studies conducted at the community level prior to transfer 
to hospital are needed in this high-risk group to adequately 
assess predictors of symptoms and signs.
In summary, our study suggests that NPS collected at the 
time of hospitalisation are likely to be of limited use in 
determining the diagnosis of pneumonia based on key 
WHO signs (tachypnoea and chest in-drawing), and for the 
duration of these signs in children with high NP microbial 
colonisation rates. Larger cohort and case-control studies 
are needed to confirm our findings.
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